CD10-A new prognostic stromal marker in breast carcinoma, its utility, limitations and role in breast cancer pathogenesis

Indian Journal of Pathology and Microbiology

Volumn 57, Issue 4, 2014, Pages 530-536

  Jana, Sayantan H ^a   Jha, Bharti M ^a   Patel, Chandni ^a   Jana, Dipan ^c   Agarwal, Anshul ^b  

^a GOVERNMENT MEDICAL COLLEGE   (India)

^b GUJARAT CANCER AND RESEARCH INSTITUTE   (India)

^c CALCUTTA NATIONAL MEDICAL COLLEGE   (India)

Author keywords

Breast carcinoma; CD10; pathogenesis; stromal marker

Indexed keywords

COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TUMOR MARKER; ERBB2 PROTEIN, HUMAN; MATRIX METALLOPROTEINASE; MEMBRANE METALLOENDOPEPTIDASE; TIMP1 PROTEIN, HUMAN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA;

AGE; ARTICLE; BREAST BIOPSY; BREAST CARCINOMA; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CARCINOGENESIS; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; MENOPAUSE; MITOSIS RATE; TUMOR BIOPSY; TUMOR VOLUME; ADULT; BIOSYNTHESIS; BREAST NEOPLASMS; EXTRACELLULAR MATRIX; FEMALE; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; TUMOR INVASION;

ADULT; BREAST NEOPLASMS; EXTRACELLULAR MATRIX; FEMALE; HUMANS; MATRIX METALLOPROTEINASES; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEPRILYSIN; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TRANSFORMING GROWTH FACTOR BETA;

EID: 84908566899     PISSN: 03774929     EISSN: 09745130     Source Type: Journal    
DOI: 10.4103/0377-4929.142639     Document Type: Article

References (30)

1. ICMR [Internet]: Two-year report of the population based cancer registries, 1999-2000, National cancer registry program me. Available from: http://www.icmr.nic.in/ncrp/1999-00/PBCR%20Report%20 1999-00.pdf [Last accessed on 2013 Nov 15]
2. College of American pathologists[certified]: Protocol for the Examination of Specimens From Patients With Invasive Carcinoma of the Breast [Protocol web posting date: June 2012]. Available from: http://www.cap.org/apps/cap.portal-144 [Last accessed in 2013 Aug]
3. Blamey RW, Ellis IO, Pinder SE, Lee AH, Macmillan RD, Morgan DA, et al. Survival of invasive breast cancer according to the Nottingham Prognostic Index in cases diagnosed in 1990-1999. Eur J Cancer 2007;43: 1548-55
4. Makretsov NA, Hayes M, Carter BA, Dabiri S, Gilks CB, Huntsman DG. Stromal CD10 expression in invasive breast carcinoma correlates with poor prognosis, estrogen receptor negativity, and high grade. Mod Pathol 2007;20: 84-9
5. Iwaya K, Ogawa H, Izumi M, Kuroda M, Mukai K. Stromal expression of CD10 in invasive breast carcinoma: A new predictor of clinical outcome. Virchows Arch 2002;440: 589-93
6. Thomas S, Babu RJ, Agarwal K, Puri V, Jain M, Andley M, et al. Effect of neoadjuvant chemotherapy on stromal CD10 antigens in breast cancer-A preliminary study. Indian J Cancer 2013;50: 46-51
7. Mott JD, Werb Z. Regulation of matrix biology by matrix metalloproteinases. Curr Opin Cell Biol 2004;16: 558-64
8. Fidler IJ. The pathogenesis of cancer metastasis: The seed and soil hypothesis revisited. Nat Rev Cancer 2003;3: 453-8
9. Bremnes RM, Dønnem T, Al-Saad S, Al-Shibli K, Andersen S, Sirera R, et al. The role of tumor stroma in cancer progression and prognosis: Emphasis on carcinoma-Associated fibroblasts and non-small cell lung cancer. J Thorac Oncol 2011;6: 209-17
10. De Wever O, Mareel M. Role of tissue stroma in cancer cell invasion. J Pathol 2003;200: 429-47
11. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004;4: 71-8
12. Jinga DC, Blidaru A, Condrea I, Ardeleanu C, Dragomir C, Szegli G, et al. MMP-9 and MMP-2 gelatinases and TIMP-1 and TIMP-2 inhibitors in breast cancer: Correlations with prognostic factors. J Cell Mol Med 2006;10: 499-510
13. Curran CS, Keely PJ. Breast tumor and stromal cell responses to TGF-?and hypoxia in matrix deposition. Matrix Biol 2013;32: 95-105
14. Kass L, Erler JT, Dembo M, Weaver VM. Mammary epithelial cell: Influence of extracellular matrix composition and organization during development and tumorigenesis. Int J Biochem Cell Biol 2007;39: 1987-94
15. Maguer-Satta V, Besançon R, Bachelard-Cascales E. Concise review: Neutral endopeptidase (CD10): A multifaceted environment actor in stem cells, physiological mechanisms, and cancer. Stem Cells 2011;29: 389-96
16. Bachelard-Cascales E, Chapellier M, Delay E, Pochon G, Voeltzel T, Puisieux A, et al. The CD10 enzyme is a key player to identify and regulate human mammary stem cells. Stem Cells 2010;28: 1081-8
17. Weil M, Itin A, Keshet E. A role for mesenchyme-derived tachykinins in tooth and mammary gland morphogenesis. Development 1995; 121: 2419-28
18. Kenny AJ, OHare MJ, Gusterson BA. Cell-surface peptidases as modulators of growth and differentiation. Lancet 1989;2: 785-7
19. Smollich M, Gotte M, Yip GW, Yong ES, Kersting C, Fischgräbe J, et al. On the role of endothelin-converting enzyme-1 (ECE-1) and neprilysin in human breast cancer. Breast Cancer Res Treat 2007;106: 361-9
20. Kesse-Adu R, Shousha S. Myoepithelial markers are expressed in at least 29% of oestrogen receptor negative invasive breast carcinoma. Mod Pathol 2004;17: 646-52
21. Sumitomo M, Shen R, Nanus DM. Involvement of neutral endopeptidase in neoplastic progression. Biochim Biophys Acta 2005;1751: 52-9
22. Ganju RK, Shpektor RG, Brenner DG, Shipp MA. CD10/neutral endopeptidase 24.11 is phosphorylated by casein kinase II and coassociates with other phosphoproteins including the lyn src-related kinase. Blood 1996;88: 4159-65
23. Zheng R, Iwase A, Shen R, Goodman OB Jr, Sugimoto N, Takuwa Y, et al. Neuropeptide-stimulated cell migration in prostate cancer cells is mediated by RhoA kinase signalling and inhibited by neutral endopeptidase. Oncogene 2006;25: 5942-52
24. Goodman OB Jr, Febbraio M, Simantov R, Zheng R, Shen R, Silverstein RL, et al. Neprilysin inhibits angiogenesis via proteolysis of fibroblast growth factor-2. J Biol Chem 2006;281: 33597-605
25. Iwase A, Shen R, Navarro D, Nanus DM. Direct binding of neutral endopeptidase24.11 to ezrin/radixin/moesin (ERM) proteins competes with the interaction of CD44 with ERM proteins. J Biol Chem 2004;279: 11898-905
26. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012;490: 61-70
27. West RB, Nuyten DS, Subramanian S, Nielsen TO, Corless CL, Rubin BP, et al. Determination of stromal signatures in breast carcinoma. PLoS Biol 2005;3: e187
28. Desmedt C, Majjaj S, Kheddoumi N, Singhal SK, Haibe-Kains B, El Ouriaghli F, et al. Characterization and clinical evaluation of CD10+stroma cells in the breast cancer microenvironment. Clin Cancer Res 2012;18: 1004-14
29. Cabioglu N, Summy J, Miller C, Parikh NU, Sahin AA, Tuzlali S, et al. CXCL-12/stromal cell-derived factor-1alpha transactivates HER2-neu in breast cancer cells by a novel pathway involving Src kinase activation. Cancer Res 2005;65: 6493-7
30. Pan C, Cardarelli PM, Nieder MH, Pickford LB, Gangwar S, King DJ, et al. CD10 is a key enzyme involved in the activation of tumor-Activated peptide prodrug CPI-0004Na and novel analogues: Implications for the design of novel peptide prodrugs for the therapy of CD10+ tumors. Cancer Res 2003;63: 5526-31